Together, thesedata suggest that the detection of a hydrophilic transmembrane mutationin EGFR in a cancer sample might be a first hint toward activatedEGFR signaling, although this will certainly not be true for all hydrophilictransmembrane mutations. The gene discussed is EGFR; the disease is cancer.